“Rising Adoption of Non-Opioid Analgesics”
The global analgesics market is witnessing steady growth, driven by the rising prevalence of chronic diseases and increasing demand for pain management solutions. A notable trend within this market is the shift towards non-opioid analgesics due to the growing concerns surrounding opioid addiction and the associated regulatory restrictions. For instance, nonsteroidal anti-inflammatory drugs (NSAIDs) such as Ibuprofen and Acetaminophen are gaining traction as safer alternatives for treating pain. The launch of ZYNRELEF by Heron Therapeutics in 2021, a non-opioid, extended-release product designed for postsurgical analgesia, providing effective pain relief for up to 72 hours. This shift is also supported by the increasing focus on over-the-counter (OTC) analgesics, which are more accessible and preferred by consumers for managing mild to moderate pain. The growing demand for safer, more effective pain management solutions is driving pharmaceutical companies to innovate, expanding the global analgesics market.
